September 3, 2008 - IntraOp will discuss at ASTRO 2008 the recent results of the study which found that a single dose of Intraoperative electron radiotherapy (IOERT) delivered in a single day may be equivalent to six weeks of standard, daily radiation for breast cancer patients.

According to the study, led by by Umberto Veronesi, M.D., director of the European Institute of Oncology in Milan, Italy, a breast surgeon who has pioneered the use of IOERT for this purpose, a single dose of intraoperative electron-beam radiation can be equal to the traditional six-week course for women with breast cancer. The only FDA-approved device available in North America that is capable of delivering the IOERT treatment extolled by Dr. Veronesi in an unshielded operating room is IntraOp’s Mobetron. The Mobetron is a fully portable, self-shielded linear accelerator that can be used in an existing operating room.

Dr. Veronesi presented the results from the first findings of his randomized trial at the recent ISIORT conference in Madrid, Spain, in June 2008. Patients were divided into two groups that received one of two types of treatment: breast conserving surgery and a single dose of IOERT; and breast conserving surgery and traditional six weeks of post-operative radiation therapy. Dr. Veronesi’s study reported that, to date, women who received a single dose of IOERT had identical control, survival and cosmetic results as those who underwent the standard six-week radiation regimen.

From these results, Dr. Veronesi concluded that a single dose of IOERT may be equivalent in outcome to six weeks of post-operative radiation therapy.

For more information: www.intraopmedical.com

Related Content

News | Proton Therapy

June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G ...

Time June 24, 2021
arrow
News | Linear Accelerators

June 18, 2021 — Elekta announced that its Elekta Harmony radiation therapy system recently received U.S. FDA 510(k) ...

Time June 18, 2021
arrow
News | Linear Accelerators

January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris ...

Time January 20, 2021
arrow
News | Linear Accelerators

January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular ...

Time January 04, 2021
arrow
News | Radiation Oncology

April 17, 2020 — PTW has installed the first Beamscan MR motorized 3-D water phantom in North America at the Princess ...

Time April 17, 2020
arrow
News | Radiation Oncology

January 30, 2020 — Elekta announced that it signed a contract with the Institut Jules Bordet, Brussels, for an Elekta ...

Time January 30, 2020
arrow
Technology | Quality Assurance (QA)

IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming American Society for Radiation Oncology (ASTRO) congress, Sept. 15-19 in Chicago.

Time September 12, 2019
arrow
Videos

Kristin Higgins, M.D., medical director of radiation oncology at the Emory Clinic at the Winship Cancer Institute, and ...

Time October 29, 2018
arrow
News | Radiation Therapy

Gustave Roussy has awarded Elekta with an order for four Versa HD linear accelerators, replacing their existing installed base of competing systems. The premier European comprehensive cancer center started its radiotherapy program in 2013.

Time September 04, 2015
arrow
News

The ECRI Institute released a new techIQ brief on key factors to consider when purchasing a linear accelerator (linac) for external beam radiation therapy. The report is a compilation of results from a survey of hundreds of users of linac-based radiosurgery systems; participants were asked to rate the functions and features of the four major linac vendors: Accuray, Brainlab, Elekta and Varian Medical Systems.

Time June 23, 2015
arrow
Subscribe Now